(Q40878401)

24 September 2017

1 reference

title

Methotrexate use in rheumatoid arthritis (English)

1 reference

24 September 2017

1 reference

O'Dell JR

1

1 reference

24 September 2017

1 November 1997

1 reference

Rheumatic Diseases Clinics of North America

24 September 2017

1 reference

24 September 2017

23

1 reference

24 September 2017

4

1 reference

24 September 2017

779-796

1 reference

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Methotrexate in rheumatoid arthritis. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Second-line drug therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Cost-effectiveness of orally administered liquid methotrexate: comment on the letters by McLaughlin and by Wase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Rheumatoid arthritis. Pathophysiology and implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Methotrexate therapy in rheumatoid arthritis: 15 years experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Small-vessel vasculitis and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Pulse methotrexate therapy in rheumatoid arthritis. A controlled prospective roentgenographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Folate supplementation in methotrexate-treated rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Methotrexate in the treatment of rheumatoid arthritis; pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970360-4

7 January 2021

10.1016/S0889-857X(05)70360-4

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9361155